SLC2A3 and rheumatoid arthritis: Additionally, since the mechanism we propose entails a loss-of-function allele that is disease protective, this recommends it as a target for drug development, that is, the inhibition of SLC2A3 expression (and/or GLUT3 activity) may provide a direct means to protect against RA in the 97%–99% of individuals without the deletion allele.